Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Sarissa Capital, holder of approximately 5% of Astex shares, said the announced merger with Otsuka significantly undervalues Astex and that it did not intend…
ASTRAL-1 missed CR and OS endpoints in treatment-naive unfit AML — a setback for Otsuka's $866M Astex deal, though Astex's Mohammad Azab pointed to 'very…
Guadecitabine has now failed three late-phase trials, leaving Otsuka 'facing the prospect of being unable to generate a return on the lead clinical program…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Otsuka to acquire Astex at $8.50/share cash (~$886M); brings SGI-110 hypomethylating agent and Pyramid fragment-based platform plus oncology/CNS pipeline.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals (this deal) | 2013 | $886M | 79 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| Shire plc / Baxalta Inc. | 2016 | $32.0B | 77 |
← Browse all deals · How we score deals
More: 2013 deals · Hematology deals